LAL-QLB with IV analgesia as good as TEA under multimodal analgesia after open liver surgery
A recent study by Bin Gu found thoracic epidural analgesia (TEA) provides better pain control than ultrasound-guided anterior quadratus lumborum block at the lateral supra-arcuate ligament (LAL-QLB) with intravenous analgesia after open liver surgery. The findings of this study was published in Journal of the American College of Surgeon.
This study was a randomized, open-label trial that included 74 patients undergoing open liver surgery who were randomized (1:1) to the LAL-QLB or TEA group. The primary outcome was the numeric rating scale during coughing at 24 hours postoperatively with a non-inferiority limit of 1.
The key highlights of the study were:
The mean difference of numeric rating scale during coughing at 24 hours postoperatively was 0.32 (95% CI –0.03 to 0.68), showing non-inferiority.
The TEA group had better pain scores at 1 and 6 hours, and the early postoperative pain of the LAL-QLB group was within the clinically acceptable limit with no differences at other time points.
The LAL-QLB group received more opioids within 24 hours postoperatively. There were no differences in analgesia-related adverse reactions or rescue analgesia.
The study also found that postoperative coagulopathy was responsible with 19.4% of delayed epidural removal. TEA outperformed LAL-QLB in terms of ambulation and bowel recovery. There were no differences in hospital stay or 30-day postoperative complications.
The study found that LAL-QLB provided non-inferior analgesia at 24 hours postoperatively. However, considering coagulopathy and delayed epidural removal, TEA was found to be better than LAL-QLB for pain management after open liver surgery. Close coagulation test were necessary for epidural removal.
Source:
Gu, B., Zhou, H., Lian, Y., Zhou, Y., He, S., Xie, K., & Jiang, H. (2022). Ultrasound-Guided Anterior Quadratus Lumborum Block at Lateral Supra-Arcuate Ligament vs Thoracic Epidural Analgesia after Open Liver Surgery: A Randomized, Controlled, Noninferiority Trial. In Journal of the American College of Surgeons. Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.1097/xcs.0000000000000354
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.